March 10, 2014 8:41 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Analysts at UBS initiated coverage on shares of Concert Pharmaceuticals (NASDAQ: CNCE) with a “buy” rating. The target price for Concert Pharma is set to $25. Concert Pharma's shares closed at $14.88 on Friday.HC Wainwright initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) with a “buy” rating. The target price for BioCryst Pharmaceuticals is set to $21. BioCryst's shares closed at $11.46 on Friday.Analysts at Cantor Fitzgerald initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) with a “buy” rating. The target price for Eagle Pharma is set to $21. Eagle Pharma's shares closed at $14.92 on Friday.Deutsche Bank initiated coverage on shares of Installed Building Products (NYSE: IBP) with a “buy” rating. The target price for Installed Building Products is set to $18. Installed Building's shares closed at $14.78 on Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.